Indian pharmaceutical companies are shifting focus from generics to biosimilars, capitalizing on upcoming patent expiries of blockbuster biologics for global growth and higher profitability.

India

Who

Indian pharmaceutical companies

What

When

Tue, 14 Jul 2026 23:34:00 GMT · 1h 45m ago

Where

India ·

Why

Upcoming patent expiries of blockbuster biologics present an opportunity for higher profitability and global growth in the biosimilars market.

The Frontline Impact

How this affects you

This strategic shift by Indian pharmaceutical companies into biosimilars could lead to increased global market share and higher profit margins for the sector.

Story chain

1 event in this thread

No related history yet - this is the origin event.

Verified Sources & Citations

The Financial Express
https://www.financialexpress.com/market/stock-insights/4-indian-pharma-stocks-eyeing-the-biggest-opportunity-since-generics/4291789/
HIGH

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.